Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity

Leuk Res. 2022 May:116:106819. doi: 10.1016/j.leukres.2022.106819. Epub 2022 Mar 3.
No abstract available

Keywords: Antibody; BNT162b2; COVID-19; MPN; Ruxolitinib; Vaccine.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • SARS-CoV-2
  • Severity of Illness Index

Substances

  • COVID-19 Vaccines
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib